Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals Inc. (ARWR) is a clinical-stage biotechnology leader developing RNA interference (RNAi) therapies that target disease-causing genes. This page provides investors and industry professionals with verified updates on the company's progress in advancing treatments for genetic disorders through its proprietary TRIM™ delivery platform.
Access consolidated, factual reporting of Arrowhead's material developments including clinical trial milestones, regulatory submissions, research collaborations, and financial disclosures. Our news aggregation ensures efficient tracking of therapeutic advancements in hepatitis B, cardiovascular diseases, and rare genetic conditions.
All content undergoes strict verification to maintain compliance with financial reporting standards. For stakeholders monitoring RNAi innovation and precision medicine breakthroughs, this resource offers centralized access to essential updates without speculative commentary.
Bookmark this page for streamlined monitoring of Arrowhead's progress in developing targeted gene silencing therapies. Check regularly for authoritative reporting on pipeline developments and strategic initiatives shaping the future of RNA-based medicine.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in key upcoming events in October 2021. On October 4, Vince Anzalone will join a fireside chat at Chardan's 5th Annual Genetics Medicines Conference. Following that, on October 12, James Hamilton will present at the H.C. Wainwright 5th Annual NASH Investor Conference. For detailed presentation materials and live webcast links, visit the Events and Presentations section on Arrowhead's website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a milestone payment of
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in several upcoming virtual investing events. Key dates include the Citi’s 16th Annual BioPharma Virtual Conference from September 8-10, with Arrowhead hosting virtual investor meetings on September 9. CEO Chris Anzalone will present during the HC Wainwright 23rd Annual Global Investment Conference on September 13 and the Cantor Virtual Global Healthcare Conference on September 29. These events will showcase Arrowhead's innovative RNA interference therapeutics targeting intractable diseases.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported financial results for Q3 2021, with revenue rising to $45.9 million compared to $27.4 million in Q3 2020. Operating loss widened to $31.9 million, and net loss increased to $29.9 million, or $(0.29) per diluted share. Notable achievements include receiving Breakthrough Therapy designation for ARO-AAT and positive interim study results for ARO-HSD and ARO-HIF2. The company maintains cash resources of $644.7 million, supporting ongoing clinical trials.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that the U.S. FDA granted Breakthrough Therapy designation for its investigational RNA interference therapeutic, ARO-AAT, co-developed with Takeda, aimed at treating alpha-1 antitrypsin deficiency (AATD)-associated liver disease. ARO-AAT also has Orphan Drug and Fast Track designations. The Phase 2 SEQUOIA study has reached full enrollment of 40 patients, with interim results suggesting a significant reduction in toxic Z-AAT protein production, potentially improving liver disease outcomes.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal third quarter ending June 30, 2021. Investors can access the live audio on the Company's website. A replay will be available shortly after the call concludes. Arrowhead focuses on developing therapies that utilize RNA interference to address intractable diseases by silencing specific genes.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced on July 1, 2021, the approval of "inducement" grants to 42 new employees by its Board of Directors’ Compensation Committee. These grants, totaling up to 157,000 restricted stock units, are outside of the company's stockholder-approved equity incentive plans and vest annually over four years. Arrowhead develops RNAi-based therapeutics targeting intractable diseases by silencing specific genes, aiming for effective gene expression inhibition.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from its Phase 1b AROHIF21001 study, evaluating ARO-HIF2 for treating clear cell renal cell carcinoma (ccRCC). The study has enrolled 17 patients, with 9 having evaluable tumor samples. Results showed that 7 of 9 patients had reductions in HIF2α protein levels, averaging 48%. Notably, one patient experienced a partial response with a 65% tumor shrinkage. Arrowhead is currently enrolling the third cohort and plans to present further data at an upcoming medical congress.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced a voluntary pause of the AROENaC1001 clinical study, a Phase 1/2 trial for its RNA interference therapy targeting cystic fibrosis. This decision follows preliminary findings from chronic toxicology studies indicating unexpected local lung inflammation in rats. The company has halted new patient screenings and further dosing while waiting for comprehensive data from ongoing toxicology studies. Despite this setback, Arrowhead remains focused on advancing its other eight clinical candidates and expanding its preclinical initiatives.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing for the first patient in its Phase 2b clinical trial, AROANG3-2001, aimed at evaluating the safety and efficacy of ARO-ANG3 for treating mixed dyslipidemia. The study will enroll about 180 participants and assess three dose levels (50 mg, 100 mg, and 200 mg) against a placebo. ARO-ANG3 targets the inhibition of ANGPTL3 to reduce triglycerides and LDL cholesterol, potentially addressing cardiovascular risks in patients with mixed dyslipidemia.
